Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.

First Posted Date
2019-09-04
Last Posted Date
2019-09-06
Lead Sponsor
Beijing Friendship Hospital
Target Recruit Count
160
Registration Number
NCT04077905
Locations
🇨🇳

Beijing Friendship Hospital, Beijing, China

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

First Posted Date
2019-08-20
Last Posted Date
2019-08-20
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
54
Registration Number
NCT04061772
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

First Posted Date
2019-08-07
Last Posted Date
2024-11-29
Lead Sponsor
BeiGene
Target Recruit Count
449
Registration Number
NCT04047862
Locations
🇺🇸

University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States

🇦🇺

St Vincents Hospital, Fitzroy, Victoria, Australia

🇨🇳

Beijing Tongren Hospital, Cmu, Beijing, Beijing, China

and more 26 locations

A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

First Posted Date
2019-08-05
Last Posted Date
2022-09-14
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
240
Registration Number
NCT04044222
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

First Posted Date
2019-07-22
Last Posted Date
2024-07-16
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
155
Registration Number
NCT04028050
Locations
🇮🇹

Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy

🇮🇹

Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy

🇮🇹

Ospedali Riuniti Di Ancona; Oncology, Ancona, Marche, Italy

and more 22 locations

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

First Posted Date
2019-06-27
Last Posted Date
2019-10-08
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
280
Registration Number
NCT04000295
Locations
🇨🇳

Sun Yat-sen University, Guangzhou, Guangdong, China

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

First Posted Date
2019-06-19
Last Posted Date
2023-07-06
Lead Sponsor
University of Washington
Target Recruit Count
24
Registration Number
NCT03991884
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Phase 2
Active, not recruiting
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Diffuse Large B-Cell Lymphoma
Double-Expressor Lymphoma
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present
Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Procedure: Lumbar Puncture
Procedure: Positron Emission Tomography
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate
Drug: Venetoclax
First Posted Date
2019-06-13
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
363
Registration Number
NCT03984448
Locations
🇺🇸

Cancer Hematology Centers - Flint, Flint, Michigan, United States

🇺🇸

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States

🇺🇸

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 633 locations

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

First Posted Date
2019-06-10
Last Posted Date
2023-02-23
Lead Sponsor
Grupo Espanol de Tumores Neuroendocrinos
Target Recruit Count
38
Registration Number
NCT03980925
Locations
🇪🇸

Institut Català d'Oncologia l'Hospitalet, Hospitalet de Llobregat, Barcelona, Spain

🇪🇸

Hospital Universitario 12 de Octubre, Madrid, Spain

🇪🇸

Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain

and more 9 locations

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

First Posted Date
2019-05-24
Last Posted Date
2019-05-24
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
112
Registration Number
NCT03963193
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy